Scientific communications

Benefit from a robust mixed leukocyte reaction assay to evaluate immunomodulatory properties of your candidates

12 / 04 / 2023

Benefit from a robust mixed leukocyte reaction assay to evaluate immunomodulatory properties of your candidates

Considering the importance of dendritic cells in fine-tuning T cell response, their manipulation represents an attractive approach to elicit or boost an anti-tumor immune response. To this end, we have developed and validated a mixed leukocyte reaction (MLR) assay to address DC function and evaluate their immune-modulatory properties.

Macrophage-based assays to assess immunotherapeutics on macrophage functions and mediated immune response

10 / 18 / 2023

Macrophage-based assays to assess immunotherapeutics on macrophage functions and mediated immune response

While mastering the key specifications of our macrophage-based models and their subtleties, our scientific and experimental expertise governs the relevance of our macrophage assays in evaluating the efficacy of immunotherapeutics either on the stimulatory M1 capacities or, especially, in relieving the suppressive functions of M2 macrophages.

How to fully exploit the mixed leukocyte reaction assay?

12 / 08 / 2022

How to fully exploit the mixed leukocyte reaction assay?

How to fully exploit the mixed leukocyte reaction assay for assessing immunotherapeutics on dendritic cell function and mediated immune response?
While immunological synapse that occurs between T lymphocytes and dendritic cells (DCs) is a key component for an effective immune response, DC subpopulations are generated involving many signaling cues whose the nature only determines their functional properties

New! Olink proteomics joins the dance of our biomarker discovery capacities

05 / 31 / 2022

New! Olink proteomics joins the dance of our biomarker discovery capacities

As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities for comprehensive protein biomarker discovery using Olink® Target technology.

Olink®’s Target96 biomarker panels are dedicated to many diseases and/or biological processes. You can directly download them from the form below and do not hesitate to let us know your proteomics projects!

Spotlight on our in vivo advances

05 / 12 / 2022

Spotlight on our in vivo advances

Development and characterization of a novel anti-PD1 resistant sarcoma mouse model

Soft Tissue Sarcoma (STS) is known to be refractory to current cancer immunotherapies including the PD1 immune checkpoint inhibitor (ICI) (Toulmonde et al., 2018), thus claiming the development of novel therapeutic strategies aiming at improving the current clinical benefit.

Strenghten your immuno-oncology research with our complete digital pathology capacities

03 / 24 / 2022

Strenghten your immuno-oncology research with our complete digital pathology capacities

Drawing on our expertise in multiplexed-immunohistofluoresence (IHF) and immunohistochemistry (IHC) assays, we have already developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets. While bringing key answers to address specific questions, our capacities have recently been highlighted in new scientific publications of collaborative works with Institut Bergonié, which we are delighted to share thereafter.

Immune cell-mediated tumor killing assays for cancer immunotherapy assessment

02 / 02 / 2022

Immune cell-mediated tumor killing assays for cancer immunotherapy assessment

While one of the promising cancer immunotherapy challenges is the potentiation of immune cell-induced tumor cell attacks, in vitro immune cell-mediated killing is recognized among the most relevant functional measures to evaluate the ability of candidate drugs to promote the functions of effector immune cells. We set up and designed specialized in vitro immune cell killing assays - either T cell- or NK-mediated - to test candidate compounds or antibodies for their immunomodulatory properties in enhancing the immune response against tumor cells.

Spatial transcriptomics reveals key determinants of response to immune checkpoint blockade in NSCLC

11 / 22 / 2021

Spatial transcriptomics reveals key determinants of response to immune checkpoint blockade in NSCLC

The development of immune checkpoint blockers (ICB) has considerably changed the therapeutic armamentarium for the management of cancer. Blocking the PD-1/PD-L1 axis interaction has demonstrated remarkable anti-cancer activity and has led to approval of anti-PD-1/PD-L1 drugs in several solid tumors. However, most patients receiving PD(L)-1 blockers do not derive clinical benefit. Therefore, there is a crucial need to decipher mechanisms underlying sensitivity / resistance to cancer immunotherapies which can ultimately lead to the identification of novel therapeutic targets.